Recombinant Cynomolgus BAFF/TNFSF13B Protein (HEK293)，hFc

BAFF (B-cell activating factor) or TNFSF13B (Tumor Necrosis Factor Superfamily member 13B) is a crucial cytokine involved in the regulation of B-cell maturation, survival, and proliferation. It acts primarily through binding to its receptors, BR3, BAFF-R, and TACI, facilitating the development of the immune system and playing a pivotal role in humoral immunity. Dysregulation of BAFF levels has been implicated in various autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, where elevated BAFF levels contribute to the survival of autoreactive B cells. Due to its significant role in both health and disease, BAFF has emerged as a potential therapeutic target. The development of recombinant BAFF proteins has provided valuable tools for research purposes, allowing for a better understanding of its signaling pathways and biological functions. These recombinant proteins can be utilized in in vitro and in vivo studies to dissect the molecular mechanisms underpinning B-cell related disorders and to evaluate the efficacy of BAFF-targeted interventions. Furthermore, the characterization of BAFF's structure and interactions with its receptors can yield insights that may lead to novel therapies aimed at modulating immune responses in autoimmune conditions and enhancing vaccine efficacy. Thus, the study of recombinant BAFF/TNFSF13B proteins is fundamentally important for both basic immunology and the development of targeted treatments for B-cell-related diseases.